release steroid that
replaces eye drops
after cataract sur-
gery with a single
shot. The FDA-
approved EyePoint
Pharmaceuticals's
Dexycu in February.
A single injection of
Dexycu administered at the site of action at the conclusion of surgery
treats post-op inflammation and dispenses with weeks of post-op eye
drops. So-called dropless surgery benefits patients by eliminating non-
compliance and dosing errors associated with the current practice of
relying on the patient self-administering drops several times daily for
weeks following cataract surgery, says the company.
"Anything to reduce drops is a win-win for all of us," says John
Kraves, BSN, the ASC manager at Northwest Eye Surgeons in Renton,
Wash.
Inveltys
Inveltys (loteprednol
etabonate ophthalmic
suspension) 1% is
another new option
for post-surgical
inflammation and pain
following ocular surgery. The FDA approved the twice-a-day topical
ocular corticosteroid in August. It's the first topical ocular corticos-
teroid with twice-daily (BID) dosing rather than standard four-times-a-
day dosing, says Kala Pharmaceuticals.
N O V E M B E R 2 0 1 8 • O U T PA T I E N T S U R G E R Y. N E T • 7 5
• EXTENDED-RELEASE STEROID Dexycu is the first long-acting intracameral product
approved by the FDA for treating inflammation following cataract surgery.
EyePoint
Pharmaceuticals
• BID CORTICOSTEROID Inveltys (loteprednol etabonate ophthalmic suspension) 1% is
the first twice-daily topical steroid for post-op eye pain.
Kala
Pharmaceuticals